Indivior (NASDAQ:INDV) Posts Quarterly Earnings Results

Indivior (NASDAQ:INDV) issued its earnings results on Thursday. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.26, FiscalAI reports. The business had revenue of $356.00 million during the quarter, compared to analysts’ expectations of $329.35 million. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%.

Indivior Stock Performance

NASDAQ:INDV traded up $0.12 during mid-day trading on Friday, hitting $35.37. 4,607,239 shares of the company’s stock traded hands, compared to its average volume of 2,693,392. The company has a fifty day moving average of $35.20 and a 200 day moving average of $35.62. Indivior has a twelve month low of $27.68 and a twelve month high of $42.81. The company has a market capitalization of $4.17 billion, a P/E ratio of 9.88 and a beta of 0.87.

Indivior Announces Dividend

The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a dividend of $8.13 per share.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INDV. Wall Street Zen lowered shares of Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays lifted their price objective on shares of Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday. Craig Hallum reissued a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.40.

Insider Buying and Selling at Indivior

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the transaction, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at $986,400.22. This trade represents a 5.74% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.74% of the company’s stock.

Indivior Company Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.